-
公开(公告)号：EP3698810A1
公开(公告)日：2020-08-26
申请号：EP20162806.2
申请日：2010-06-18
发明人： WALENSKY, Loren, D. , BIRD, Gregory
摘要： The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.
-
2.发明公开METHODS OF MODULATING CELLULAR HOMEOSTATIC PATHWAYS AND CELLULAR SURVIVAL 有权一个BAD BH3结构域肽使用的治疗或爆发糖尿病的延时。
公开(公告)号：EP2152294A2
公开(公告)日：2010-02-17
申请号：EP08747445.8
申请日：2008-05-02
CPC分类号： A61K38/1761
摘要： The invention provides composition and therapeutic, methods for modulating homeostatic pathways that are useful in treatment, and prevention of diabetes, diabetes associated disorders, metabolic disorders and cancer.
摘要翻译： 本发明提供了组合物和治疗性的，用于调节稳态的途径的方法确实是有用的治疗和预防糖尿病，糖尿病相关的疾病，代谢疾病和癌症。
-
公开(公告)号：EP2590997B1
公开(公告)日：2018-04-04
申请号：EP11804451.0
申请日：2011-07-08
发明人： WALENSKY, Loren, D. , BIRD, Gregory
IPC分类号： C07K14/605 , C07K14/575 , C07K14/62 , A61K38/26 , A61K38/22 , A61P3/10
CPC分类号： C07K14/605 , A61K38/00 , C07K14/575 , C07K14/57563
摘要： The present invention provides stably cross-linked insulionotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.
-
公开(公告)号：EP3698811A1
公开(公告)日：2020-08-26
申请号：EP20162812.0
申请日：2010-06-18
发明人： WALENSKY, Loren, D. , BIRD, Gregory
摘要： The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.
-
公开(公告)号：EP3551213A1
公开(公告)日：2019-10-16
申请号：EP17879332.9
申请日：2017-12-07
IPC分类号： A61K38/17 , C07K14/47 , C07K14/435
-
6.发明授权A BAD BH3 DOMAIN PEPTIDE FOR USE IN TREATING OR DELAYING THE ONSET OF DIABETES. 有权一种用于治疗或延缓糖尿病发作的不良BH3域肽。
-
公开(公告)号：EP2590997A2
公开(公告)日：2013-05-15
申请号：EP11804451.0
申请日：2011-07-08
发明人： WALENSKY, Loren, D. , BIRD, Gregory
IPC分类号： C07K14/605 , C07K14/575 , C07K14/62 , A61K38/26 , A61K38/22 , A61P3/10
CPC分类号： C07K14/605 , A61K38/00 , C07K14/575 , C07K14/57563
摘要： The present invention provides stably cross-linked insulionotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.
-
公开(公告)号：EP2442829A2
公开(公告)日：2012-04-25
申请号：EP10790287.6
申请日：2010-06-18
发明人： WALENSKY, Loren, D. , BIRD, Gregory
IPC分类号： A61K39/42
CPC分类号： C07K16/1045 , A61K39/12 , A61K39/21 , C07K16/1063 , C07K2317/34 , C07K2317/76 , C12N2740/16034 , C12N2740/16122 , C12N2740/16134
摘要： The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.023 秒)
